We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 100% below its sector, cheaper than its peers on earnings.
IntegraGen S.A. provides advanced human genome analysis services to academic researchers and life science businesses across France. Their comprehensive genomic offerings include transcriptomics, epigenomics, DNA sequencing, next-generation sequencing (NGS) specifically for cancer research, and SNP genotyping. The company also delivers clinical research solutions, such as clinical-grade sequencing and pharmacogenomic studies, in addition to supporting fundamental human genetic investigations. For agricultural applications, IntegraGen offers agrigenomic services covering crop and livestock genotyping, as well as high-throughput sequencing for these domains. Their microbial genomics division conducts whole-genome microbial sequencing and transcriptomics. IntegraGen further develops a suite of sophisticated bioinformatics tools: MERCURY is an online platform for oncology, designed to transform raw high-throughput sequencing data into molecular reports for translational and clinical research. SIRIUS, a cloud-based software, empowers researchers to analyze whole genome, whole exome, and gene panel sequencing information. Galileo is another cloud application that enables dynamic exploration of RNA-Seq expression data. Finally, GeCo, their genomic consulting service, provides researchers access to expert biostatisticians and bioanalysts. Founded in 2000 and headquartered in Évry, France, IntegraGen S.A. is a subsidiary of OncoDNA SA.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save ALINT.PA and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
